TCGA-CQ-5324-01A-01R-1686-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.520
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.470
- INTERFERON_ALPHA_RESPONSE+0.460
- ANDROGEN_RESPONSE+0.430
- INTERFERON_GAMMA_RESPONSE+0.400
- CHOLESTEROL_HOMEOSTASIS+0.380
- NOTCH_SIGNALING+0.370
- MITOTIC_SPINDLE+0.360
- IL2_STAT5_SIGNALING+0.340
- MTORC1_SIGNALING+0.340
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.190
- KRAS_SIGNALING_DN-0.090
- UV_RESPONSE_UP-0.020
- MYOGENESIS+0.000
- DNA_REPAIR+0.020
- SPERMATOGENESIS+0.060
- BILE_ACID_METABOLISM+0.090
- HEME_METABOLISM+0.100
- E2F_TARGETS+0.110
- WNT_BETA_CATENIN_SIGNALING+0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-ZF-AA56-01A-31R-A39I-07 | — | — | 0.946 |
| 2 | 443B59BB-0BFD-459A-896E-FA07AA6C3A45 | — | — | 0.911 |
| 3 | 2DAB6792-F9AF-4565-BDD5-C9802F3132F4 | — | — | 0.895 |
| 4 | 59B8FDC4-299D-45B9-9AC1-526B7ED652CE | — | — | 0.891 |
| 5 | 3E605854-CC65-4951-8EDB-235FD21FD71F | — | — | 0.891 |
| 6 | 6727027F-4BAB-41ED-87F3-ECC7B1718ECF | — | — | 0.890 |
| 7 | C6A60028-2402-4048-90DF-F2B3712FB530 | — | — | 0.890 |
| 8 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.888 |
| 9 | A7C71CEF-A5C7-4BAC-9090-9808B029190B | — | — | 0.885 |
| 10 | TCGA-FD-A5BU-01A-31R-A26T-07 | — | — | 0.885 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 46 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.520 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.470 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.430 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.380 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.370 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.340 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.340 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| APOPTOSIS | 0.330 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.330 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.320 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.310 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |